Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Three Months Ended March 31,

Cash payments included in the measurement of operating lease liabilities

LEASES (Tables)

3 Months Ended

Mar. 31, 2022

The components of our operating lease expense were as follows (in thousands):


	Three Months Ended March 31,
	2022		2021
Fixed operating lease expense	$	1,340	$	1,340
Variable operating lease expense		266		229
Total operating lease expense	$	1,606	$	1,569

Supplemental information related to our operating lease were as follow (in thousands):

Supplemental information related to our operating sublease was as follow (in thousands):

The following table presents the future lease payments of our operating lease liabilities as of March 31, 2022 (in thousands):


		Operating Lease		Sublease Receipts		Net
Remainder of 2022	$	7,889		(3,548)		4,341
2023		877		(394)		483
Total minimum payments required	$	8,766	$	(3,942)	$	4,824